<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        80-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALMETRA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEMETREXED
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2595.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jiangsu Hansoh Pharmaceutical Group Co" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jiangsu Hansoh Pharmaceutical Group Co
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Almetra</strong>&reg; for Injection is a medicine used in the treatment of can&shy;cer.</p><p><strong>Almetra</strong>&reg; for Injection is given in combination with cisplatin, an&shy;other anti-cancer medicine, as treatment for malignant pleural me&shy;sothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.</p><p><strong>Almetra</strong>&reg; for Injection is also given in combination with cispla&shy;tin for the initial treatment of patients with advanced stage of lung cancer.</p><p><strong>Almetra</strong>&reg; can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.</p><p><strong>Almetra</strong>&reg; for Injection is also a treatment for patients with ad&shy;vanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Almetra</strong>&reg; <strong>for Injection</strong></p><p>-if you are allergic (hypersensitive) to pemetrexed or any of the other ingredients of this medicine (listed in section 6).</p><p>- if you are breast-feeding; you must discontinue breast-feeding dur&shy;ing treatment with <strong>Almetra</strong>&reg; for Injection.</p><p>- if you have recently received or are about to receive a vaccine against yellow fever.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or hospital pharmacist before receiving</p><p><strong>Almetra</strong>&reg; for Injection.</p><p>If you currently have or have previously had problems with your kid&shy;neys, talk to your doctor or hospital pharmacist as you may not be able to receive Pememtrexed for Injection.</p><p>Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pememtrexed for In&shy;jection. Your doctor may decide to change the dose or delay treat&shy;ing you depending on your general condition and if your blood cell counts are too low. If you are also receiving cisplatin, your doctor will make sure that you are properly hydrated and receive appropriate treatment before and after receiving cisplatin to prevent vomiting.</p><p>If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Pememtrexed for Injection.</p><p>If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Pememtrexed for Injection.</p><p>If you have heart disease or a history of heart disease, please tell your doctor.</p><p>If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Pememtrexed for Injection.</p><p><strong>Children and adolescents</strong></p><p>There is no relevant use of Pememtrexed for Injection in the pedi&shy;atric population</p><p><strong>Other medicines and Pememtrexed for Injection</strong></p><p>Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called &ldquo;nonsteroidal anti-inflammatory drugs&rdquo; (NSAIDs), including medicines purchased without a doctor&rsquo;s prescription (such as ibuprofen). There are many sorts of NSAIDs with different durations of activity. Based on the planned date of your infusion of Pememtrexed for Injection and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. If you are unsure, ask your doctor or pharmacist if any of your medi&shy;cines are NSAIDs.</p><p>Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines ob&shy;tained without a prescription.</p><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. The use of Pememtrexed for Injection should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking Pememtrexed for Injection during pregnancy. Women must use effective contraception during treat&shy;ment with Pememtrexed for Injection.</p><p><strong>Breast-feeding</strong></p><p>If you are breast-feeding, tell your doctor.</p><p>Breast-feeding must be discontinued during Pememtrexed for Injec&shy;tion treatment.</p><p><strong>Fertility</strong></p><p>Men are advised not to father a child during and up to 6 months fol&shy;lowing treatment with <strong>Almetra&reg; </strong>and should therefore use effective contraception during treatment with Pememtrexed for Injection and for up to 6 months afterwards. If you would like to father a child dur&shy;ing the treatment or in the 6 months following receipt of treatment, seek advice from your doctor or pharmacist. You may want to seek counselling on sperm storage before starting your therapy.</p><p><strong>Driving and using machines</strong></p><p><strong>Almetra&reg; </strong>may make you feel tired. Be careful when driving a car or using machines.</p><p><strong>Almetra&reg; for Injection contains sodium</strong></p><p><strong>Almetra&reg; </strong>for Injection 500 mg contains approximately 54 mg so&shy;dium per vial. To be taken into consideration by patients on a con&shy;trolled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>The dose of <strong>Almetra&reg; </strong>for Injection is 500 milligrams for every square metre of your body&rsquo;s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. A hospital pharmacist, nurse or doctor will have mixed the Pememtrexed for Injection powder with 9 mg/ml (0.9 %) sodium chloride solution for injection before it is given to you.</p><p>You will always receive <strong>Almetra&reg; </strong>for Injection by infusion into one of your veins. The infusion will last approximately 10 minutes.</p><p><strong>When using Almetra&reg; for Injection in combination with cis&shy;platin:</strong></p><p>The doctor or hospital pharmacist will work out the dose you need based on your height and weight. Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pememtrexed for Injection has finished. The infusion of cisplatin will last approximately 2 hours.</p><p>You should usually receive your infusion once every 3 weeks.</p><p><strong>Additional medicines:</strong></p><p>Corticosteriods: your doctor will prescribe you steroid tablets (equiv&shy;alent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after Pememtrexed for Injection treatment. This medicine is given to you to reduce the frequency and severity of skin reactions that you may experience during your anticancer treatment.</p><p>Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1000 micrograms) that you must take once a day while you are taking Pememtrexed for Injection. You must take at least 5 doses during the seven days before the first dose of Pememtrexed for Injection. You must continue taking the folic acid for 21 days after the last dose of Pememtrexed for Injection. You will also receive an injection of vitamin B12 (1000 micrograms) in the week before administra&shy;tion of Pememtrexed for Injection and then approximately every 9 weeks (corresponding to 3 courses of Pememtrexed for Injection treatment). Vitamin B12 and folic acid are given to you to reduce the possible toxic effects of the anticancer treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. You must contact your doctor immediately if you notice any of the following:</p><p>&bull;Fever or infection (common): if you have a temperature of 38&ordm;C or greater, sweating or other signs of infection(since you might have less white blood cells than normal which is very common). Infection (sepsis) may be severe and could lead to death.</p><p>&bull;If you start feeling chest pain (common) or having a fast heart rate (uncommon).</p><p>&bull;If you have pain, redness, swelling or sores in your mouth (very common).</p><p>&bull;Allergic reaction: if you develop skin rash (very common) / burning or prickling sensation (common), or fever (common). Rarely, skin re&shy;actions may be severe and could lead to death. Contact your doctor if you get a severe rash, or itching, or blistering (Stevens - Johnson syndrome or Toxic epidermal necrolysis).</p><p>&bull;If you experience tiredness, feeling faint, becoming easily breath&shy;less or if you look pale (since you might have less hemoglobin than normal which is very common).</p><p>&bull;If you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common).</p><p>&bull;If you experience sudden breathlessness, intense chest pain or cough with bloody sputum (uncommon) (may indicate a blood clot in the blood vessels of the lungs).</p><p>Side effects with <strong>Almetra&reg; </strong>may include:</p><p>Very common (may affect more than 1 in 10 people)</p><p>&bull;Low white blood cells</p><p>&bull;Low haemoglobin level (anaemia)</p><p>&bull;Low platelet count</p><p>&bull;Diarrhoea</p><p>&bull;Vomiting</p><p>&bull;Pain, redness, swelling or sores in your mouth</p><p>&bull;Nausea</p><p>&bull;Loss of appetite</p><p>&bull;Fatigue (tiredness)</p><p>&bull;Skin rash</p><p>&bull;Hair loss</p><p>&bull;Constipation</p><p>&bull;Loss of sensation</p><p>&bull;Kidney: abnormal blood tests</p><p>Common (may affect up to 1 in 10 people)</p><p>&bull;Allergic reaction: skin rash / burning or prickling sensation</p><p>&bull;Infection including sepsis</p><p>&bull;Fever</p><p>&bull;Dehydration</p><p>&bull;Kidney failure</p><p>&bull;Irritation of the skin and itching</p><p>&bull;Chest pain</p><p>&bull;Muscle weakness</p><p>&bull;Conjunctivitis (inflamed eye)</p><p>&bull;Upset stomach</p><p>&bull;Pain in the abdomen</p><p>&bull;Taste change</p><p>&bull;Liver: abnormal blood tests</p><p>&bull;Watery eyes</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&bull;Acute renal failure</p><p>&bull;Fast heart rate</p><p>&bull;Inflammation of the lining of the oesophagus (gullet) has been ex&shy;perienced with <strong>Almetra&reg; </strong>/ radiation therapy.</p><p>&bull;Colitis (inflammation of the lining of the large bowel, which may be accompanied by intestinal or rectal bleeding)</p><p>&bull;Interstitial pneumonitis (scarring of the air sacs of the lung)</p><p>&bull;Oedema (excess fluid in body tissue, causing swelling)Some pa&shy;tients have experienced a heart attack, stroke or &ldquo;mini-stroke&rdquo; while receiving <strong>Almetra&reg; </strong>usually in combination with another anticancer therapy.</p><p>&bull;Pancytopenia- combined low counts of white cells, red cells and platelets.</p><p>&bull;Radiation pneumonitis (scarring of the air sacs of the lung asso&shy;ciated with radiation therapy) may occur in patients who are also treated with radiation before, during or after their Pememtrexed for Injection therapy.</p><p>&bull;Extremity pain, low temperature and discolouration have been re&shy;ported.</p><p>&bull;Blood clots in the lung blood vessels (pulmonary embolism).</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>&bull;Radiation recall (a skin rash like severe sunburn) which can occur on skin that has previously been exposed to radiotherapy, from days to years after the radiation.</p><p>&bull;Bullous conditions (blistering skin diseases)-including Stevens-Johnson syndrome and Toxic epidermal necrolysis.</p><p>&bull;Immune mediated haemolytic anaemia (antibody-mediated de&shy;struction of red blood cells).</p><p>&bull;Hepatitis (inflammation of the liver).</p><p>&bull;Anaphylactic shock (severe allergic reaction).</p><p>Not known: frequency cannot be estimated from the available data</p><p>&bull;Lower limb swelling with pain and redness</p><p>&bull;Increased urine output</p><p>&bull;Thirst and increased water consumption</p><p>&bull;Hypernatraemia &ndash; increased sodium in blood</p><p>You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.</p><p>If you are concerned about any side effects, talk to your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;Keep this medicine out of the sight and reach of children.</p><p>&bull;Do not use this medicine after the expiry date which is stated on the label and carton.</p><p>&bull;This medicine does not require any special storage conditions.</p><p>&bull;Reconstituted and Infusion Solutions: The product should be used immediately. When prepared as directed, chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at 2&deg;to 8&deg;C.</p><p>&bull;This medicine is for single use only; any unused solution must be disposed of in accordance with local requirement.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong>Almetra&reg; <strong>contains</strong></p><p>The active substance is pemetrexed.</p><p>Almetra&reg; <strong>500 mg: </strong>Each vial contains 500 milligrams of pemetrexed (as pemetrexed disodium).</p><p>After reconstitution, the solution contains 25 mg/ml of pemetrexed. Further dilution by a healthcare provider is required prior to administration.</p><p>The other ingredients are mannitol, hydrochloric acid and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Almetra® for Injection looks like and contents of the pack
Pememtrexed for Injection is a powder for concentrate for solution for infusion in a vial. It is a White or off white lyophilized solid in colorless vial with grey rubber stopper and seal with aluminum flip-off seal.
Each pack of Almetra® consists of one Almetra® vial.
Not all pack sizes may be marketed.
The following information is intended for medical or healthcare professionals only:
Instructions for use, handling and disposal.
1.Use aseptic techniques during the reconstitution and further dilution of Almetra® for intravenous infusion administration.
2.Calculate the dose and the number of Almetra® for Injection vials needed. Each vial contains an excess of Almetra® to facilitate delivery of the label amount.
3. Almetra® for Injection 500 mg:
Reconstitute each 500 mg vial with 20 ml of 9 mg/ml (0.9%) sodium chloride solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality. The pH of the reconstituted solution is between 6.6 and 7.8. Further dilution is required.
4.The appropriate volume of reconstituted Almetra® solution must be further diluted to 100 ml with 9 mg/ml (0.9 %) sodium chloride solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.
5.Almetra® infusion solutions prepared as directed above are compatible with polyvinyl chloride and polyolefin lined administration sets and infusion bags. Pemetrexed is incompatible with diluents containing calcium, including lactated Ringer’s Injection and Ringer’s Injection.
6.Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. If particulate matter is observed, do not administer.
7.Almetra® solutions are for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.
Preparation and administration precautions: As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of Almetra® infusion solutions. The use of gloves is recommended. If a Almetra® solution contacts the skin, wash the skin immediately and thoroughly with soap and water. If pemetrexed solutions contact the mucous membranes, flush thoroughly with water. Pemetrexed is not a vesicant. There is not a specific antidote for extravasation of pemetrexed. There have been a few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator. Extravasation should be managed by local standard practice as with other non-vesicants.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturing by</strong></p><p>Jiangsu Hansoh Pharmaceutical Group Co., Ltd.- Jiangsu- China <strong>for</strong> MS Pharma-Saudi</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong></p><p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May,2021
SPM

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">الميترا للحقن هو دواء يستخدم في علاج السرطان.</p><p dir="RTL">يتم إعطاء الميترا للحقن بالتشارك مع سيسبلاتين، وهو دواء آخر لمكافحة السرطان، كعلاج لورم الظهارة المتوسطة الجنبي الخبيث، وهو شكل من أشكال السرطان الذي يؤثر على بطانة الرئة، للمرضى الذين لم يتلقوا العلاج الكيميائي السابق.</p><p dir="RTL">يعطى أيضا الميترا للحقن بالتشارك مع سيسبلاتين للعلاج الأولي للمرضى الذين يعانون من مرحلة متقدمة من سرطان الرئة.</p><p dir="RTL">يمكن وصف الميترا لك إذا كنت مصابًا بسرطان الرئة في مرحلة متقدمة وإذا كان المرض قد استجاب للعلاج أو أنه لم يتغير إلى حد كبير بعد العلاج الكيميائي الأولي.</p><p dir="RTL">الميترا للحقن هو أيضا علاج للمرضى الذين يعانون من مرحلة متقدمة من سرطان الرئة الذي تقدم المرض بعد استخدام علاج كيميائي أولي آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong><strong> </strong><strong>تستخدم</strong><strong> </strong><strong>الميترا</strong><strong> </strong><strong>للحقن</strong></p><p dir="RTL"><strong>-</strong>إذا كان لديك حساسية) فرط الحساسية (لمادة بيميتريكسيد أو لأي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6)</p><p dir="RTL">-إذا كنت ترضعين رضاعة طبيعية؛ يجب عليك التوقف عن الرضاعة الطبيعية أثناء العلاج مع الميترا للحقن.</p><p dir="RTL">-إذا كنت قد تلقيت مؤخراً أو على وشك الحصول على لقاح ضد الحمى الصفراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير</strong><strong> </strong><strong>والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو صيدلي المستشفى قبل أن تحصل على <strong>الميترا</strong><strong> </strong>للحقن.</p><p dir="RTL">إذا كنت تعاني حاليًا من مشاكل في الكليتين أو سبق لك أن واجهتها، تحدث إلى طبيبك أو صيدلي</p><p dir="RTL">المستشفى حيث قد لا تتمكن من تلقي بيميتريكسيد للحقن.</p><p dir="RTL">قبل كل عملية تسريب، سنحصل على عينات من دمك لتقييم ما إذا كان لديك وظائف كافية للكلى والكبد</p><p dir="RTL">وللتحقق من وجود ما يكفي من خلايا الدم لتلقي بيميتريكسيد للحقن. قد يقرر طبيبك تغيير الجرعة أو</p><p dir="RTL">التأخير في علاجك وفقًا لحالتك العامة وإذا كانت أعداد خلايا الدم لديك منخفضة جدًا. إذا كنت تتلقى</p><p dir="RTL">أيضا سيسبلاتين، فإن طبيبك سوف يتأكد من أنك مميه بشكل صحيح وأنك تتلقى العلاج المناسب قبل</p><p dir="RTL">وبعد تلقي سيسبلاتين لمنع القيء.</p><p dir="RTL">إذا كنت قد عالجت أو ستحصل على علاج إشعاعي، فيرجى إخبار طبيبك، حيث قد يكون هناك تفاعل</p><p dir="RTL">إشعاعي مبكر أو متأخر مع بيميتريكسيد للحقن.</p><p dir="RTL">إذا كنت قد تلقيت مطعوما حديثًا، فيرجى إخبار طبيبك، لأن ذلك قد يتسبب في تأثيرات سيئة على</p><p dir="RTL">بيميتريكسيد للحقن.</p><p dir="RTL">إذا كنت تعاني من مرض قلبي أو تاريخ من أمراض القلب، يرجى إخبار طبيبك.</p><p dir="RTL">إذا كان لديك تراكم السوائل حول رئتيك، فقد يقرر الطبيب إزالة السائل قبل إعطائك بيميتريكسيد للحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">لا يوجد أي استخدام ذا صلة <strong>الميترا</strong><strong> </strong>في فئة الأطفال</p><p dir="RTL"><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الميترا</strong></p><p dir="RTL">من فضلك أخبر طبيبك إذا كنت تتناول أي دواء للألم أو الالتهاب (التورم)، مثل الأدوية المسماة &raquo; الأدوية المضادة للالتهاب غير الستيرويدية &laquo; (المسكنات )، وصفة الطبيب )مثل الأيبوبروفين(. هناك أنواع كثيرة من مضادات الالتهاب غير الستيرويدية تمتلك فترات مختلفة من النشاط. استنادًا إلى التاريخ المخطط للتسريب من <strong>الميترا</strong><strong> </strong>و / أو حول حالة وظائف الكلى، يحتاج طبيبك إلى تقديم النصح بشأن الأدوية التي يمكنك تناولها ومتى يمكنك تناولها.</p><p dir="RTL">إذا لم تكن متأكداً، فاستشر طبيبك أو الصيدلي إذا كان أي من الأدوية الخاصة بك هي من مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">من فضلك أخبر طبيبك أو صيدلي المستشفى إذا كنت تتناول أو أخذت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا كنتِ حاملاً، تظنين بأنك قد تكونين حاملاً أو تخططين لإنجاب طفل، أخبري طبيبك. يجب تجنب استخدام <strong>الميترا</strong><strong> </strong>أثناء الحمل. سوف يناقش الطبيب معك المخاطر المحتملة لأخذ <strong>الميترا</strong><strong> </strong>أثناء الحمل. يجب على النساء استخدام وسائل منع الحمل الفعالة أثناء العلاج مع بيميتريكسيد للحقن.</p><p dir="RTL"><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">إذا كنت تقومين بالرضاعة الطبيعية، أخبري طبيبك.</p><p dir="RTL">يجب التوقف عن الرضاعة الطبيعية خلال العلاج مع <strong>الميترا</strong><strong> </strong>.</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">يُنصح الرجال بعدم الاخصاب خلال فترة تصل إلى 6 أشهر بعد العلاج باستخدام <strong>الميترا</strong><strong> </strong>، لذلك يجب استخدام وسائل منع حمل فعالة أثناء العلاج باستخدام <strong>الميترا</strong><strong> </strong>ولمدة تصل إلى 6 أشهر بعد ذلك. إذا كنت ترغب في رعاية طفل أثناء العلاج أو خلال الستة أشهر التالية لتلقي العلاج، فاطلب النصيحة من طبيبك أو الصيدلي. قد ترغب في طلب المشورة بشأن تخزين الحيوانات المنوية قبل بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد يجعلك <strong>الميترا</strong><strong> </strong>تشعر بالتعب. كن حذرا عند قيادة السيارة أو استخدام الآلات.</p><p dir="RTL"><strong>الميترا</strong><strong> </strong>يحتوي على الصوديوم</p><p dir="RTL"><strong>الميترا</strong><strong> </strong>500 ملغم يحتوي على حوالي 54 ملغم من الصوديوم في القارورة. ليأخذ بعين الاعتبار من قبل المرضى الموضوعين على نظام غذائي مسيطر على الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جرعة <strong>الميترا</strong><strong> </strong>للحقن هي 500 ملغم لكل متر مربع من مساحة سطح الجسم. يتم قياس الطول والوزن الخاصين بك لحساب مساحة سطح الجسم. سيستخدم طبيبك منطقة سطح الجسم هذه لتحديد الجرعة المناسبة لك. قد يتم تعديل هذه الجرعة، أو قد يتأخر العلاج اعتمادًا على عدد خلايا الدم وعلى حالتك العامة. سوف يمزج صيدلي أو ممرض أو طبيب المستشفى مسحوق بيميتريكسيد للحقن بمحلول كلوريد الصوديوم 9 ملغم / مل ) 0.9 ٪( للحقن قبل إعطاؤه لك.</p><p dir="RTL">سوف تتلقى دائما <strong>الميترا</strong><strong> </strong>للحقن عن طريق التسريب في واحد من عروقك. سيستمر التسريب</p><p dir="RTL">حوالي 10 دقائق.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عند</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الميترا</strong><strong> </strong><strong>للحقن</strong><strong> </strong><strong>بالتشارك</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>سيسبلاتين</strong><strong>:</strong></p><p dir="RTL">سيعمل الطبيب أو صيدلي المستشفى على تحديد الجرعة التي تحتاجها بناءً على طولك ووزنك. يتم إعطاء سيسبلاتين أيضا عن طريق التسريب في أحد الأوردة، ويتم إعطاؤه بعد 30 دقيقة تقريبًا من انتهاء تسريب <strong>الميترا</strong><strong> </strong>. سيستمر تسريب سيسبلاتين حوالي ساعتين.</p><p dir="RTL"><strong>يجب</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تتلقى</strong><strong> </strong><strong>عادةً</strong><strong> </strong><strong>التسريب</strong><strong> </strong><strong>مرة</strong><strong> </strong><strong>واحدة</strong><strong> </strong><strong>كل</strong><strong> 3 </strong><strong>أسابيع</strong><strong>.</strong></p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الإضافية</strong><strong>:</strong></p><p dir="RTL">الستيرويدات القشرية: سيصف لك طبيبك أقراص الستيرويد )ما يعادل 4 ملغم من ديكساميثازون مرتين في اليوم( التي ستحتاج إلى تناولها في اليوم السابق، وفي اليوم التالي ليوم تسريب <strong>الميترا</strong><strong> </strong>. يتم إعطاؤك هذا الدواء لتقليل تواتر وشدة تفاعلات الجلد التي قد تواجهها أثناء علاجك بمضاد السرطان.</p><p dir="RTL">المكملات الفيتامينية: سيصف لك طبيبك حمض الفوليك عن طريق الفم )فيتامين( أو مكمل فيتاميني يحتوي على حمض الفوليك ) 350 إلى 1000 ميكروغرام( الذي يجب أن تتناوله مرة واحدة في اليوم بينما تتناول <strong>الميترا</strong><strong> </strong>. يجب تناول 5 جرعات على الأقل خلال الأيام السبعة السابقة للجرعة الأولى من <strong>الميترا</strong><strong> </strong>.</p><p dir="RTL">يجب الاستمرار في تناول حمض الفوليك لمدة 21 يومًا بعد آخر جرعة من <strong>الميترا</strong><strong> </strong>.</p><p dir="RTL">سوف تتلقى أيضا حقنة من فيتامين ب 12 ( 1000ميكروغرام) في الأسبوع قبل إعطاء الميترا ثم تقريبا كل 9 أسابيع )المقابلة ل 3 دورات من علاج <strong>الميترا</strong><strong> </strong>(.</p><p dir="RTL">يتم إعطاءك فيتامين ب 12 وحمض الفوليك لتقليل التأثيرات السامة المحتملة للعلاج المضاد للسرطان.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها في الجميع.</p><p dir="RTL">يجب عليك الاتصال بالطبيب على الفور إذا لاحظت أيًا مما يلي:</p><p dir="RTL">&bull;الحمي أو العدوي (شائعة): إذا كان ديك درجة حرارة تبلغ 38 درجة مئوية أو أعلي، أو تعرق أو أي علامات من علامات الالتهاب الأخري (حيث قد تكون لديك خلايا دم بيضاء أقل مما هو شائع).</p><p dir="RTL">قد تكون العدوي (تسمم الدم) شديدة ويمكن أن تؤدي إلي الوفاة.</p><p dir="RTL">&bull;إذا بدأت تشعر بألم في الصدر) شائع (أو لديك معدل ضربات قلب سريع) غير شائع (.</p><p dir="RTL">&bull;إذا كان لديك ألم أو احمرار أو تورم أو تقرحات في الفم) شائع جدًا (.</p><p dir="RTL">&bull;رد الفعل التحسسي: إذا كنت مصاب بالطفح الجلدي) شائع جداً (/ حرقان أو إحساس بالوخز) شائع (أو حمى) شائعة (.</p><p dir="RTL">&nbsp;نادرًا ما تكون تفاعلات الجلد شديدة ويمكن أن تؤدي إلى الوفاة. اتصل بطبيبك</p><p dir="RTL">إذا كنت تعاني من طفح جلدي حاد، أو حكة، أو تقرحات )متلازمة ستيفنز جونسون أو انحلال البشرة النخري السمي(.</p><p dir="RTL">&bull;إذا شعرت بالتعب أو الإغماء أو التنفس بصعوبة أو إذا بديت شاحبا) حيث قد يكون لديك خضاب</p><p dir="RTL">أقل من المعتاد(.</p><p dir="RTL">&bull;إذا اختبرت النزيف من اللثة أو الأنف أو الفم أو أي نزيف لا يتوقف، لون البول ضارب إلى</p><p dir="RTL">الحمرة أو وردي اللون، ظهور كدمات غير متوقعة )حيث قد يكون لديك صفيحات أقل من الطبيعي</p><p dir="RTL">وهو أمر شائع جدًا(.</p><p dir="RTL">&bull;إذا كنت تعاني من ضيق التنفس المفاجئ أو الألم الشديد في الصدر أو السعال مع بصاق دموي) غير</p><p dir="RTL">شائعة) (قد تشير إلى تجلط الدم في الأوعية الدموية للرئتين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تشمل</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الميترا</strong><strong> :</strong></p><p dir="RTL">شائعة جدا &nbsp;)قد تؤثر على أكثر من 1 من كل 10 أشخاص(</p><p dir="RTL">&bull;انخفاض خلايا الدم البيضاء</p><p dir="RTL">&bull;انخفاض مستوى الهيموغلوبين) فقر الدم (انخفاض عدد الصفائح الدموية</p><p dir="RTL">&bull;إسهال</p><p dir="RTL">&bull;التقيؤ</p><p dir="RTL">&bull;ألم أو احمرار أو تورم أو تقرحات في الفم</p><p dir="RTL">&bull;الغثيان</p><p dir="RTL">&bull;فقدان الشهية</p><p dir="RTL">&bull;التعب) الإرهاق (طفح جلدي</p><p dir="RTL">&bull;تساقط الشعر</p><p dir="RTL">&bull;الإمساك</p><p dir="RTL">&bull;فقدان الإحساس</p><p dir="RTL">&bull;الكلى: اختبارات دم غير طبيعية</p><p dir="RTL">شائعة )قد تؤثر على شخص واحد من كل 10 أشخاص(</p><p dir="RTL">&bull;رد فعل تحسسي: طفح جلدي / حرقان أو إحساس بالوخز</p><p dir="RTL">&bull;العدوى بما في ذلك تسمم الدم</p><p dir="RTL">&bull;حمى</p><p dir="RTL">&bull;جفاف</p><p dir="RTL">&bull;فشل كلوي</p><p dir="RTL">&bull;تهيج الجلد والحكة</p><p dir="RTL">&bull;ألم في الصدر</p><p dir="RTL">&bull;ضعف العضلات</p><p dir="RTL">&bull;التهاب الملتحمة) التهاب في العين (</p><p dir="RTL">&bull;اضطراب في المعدة</p><p dir="RTL">&bull;ألم في البطن</p><p dir="RTL">&bull;تغيير التذوق</p><p dir="RTL">&bull;الكبد: اختبارات دم غير طبيعية</p><p dir="RTL">&bull;عيون دامعة</p><p dir="RTL">غير شائعة )قد تؤثر على شخص واحد من بين كل 100 شخص(</p><p dir="RTL">&bull;فشل كلوي حاد</p><p dir="RTL">&bull;معدل ضربات القلب سريعة</p><p dir="RTL">&bull;تمت ملاحظة حدوث التهاب بطانة المريء مع <strong>الميترا</strong><strong> </strong>/ العلاج الإشعاعي.</p><p dir="RTL">&bull;التهاب القولون) التهاب بطانة الأمعاء الغليظة، والذي قد يصاحبه نزيف معوي أو مستقيمي (</p><p dir="RTL">&bull;التهاب رئوي خلالي) تندب الأكياس الهوائية للرئة (</p><p dir="RTL">&bull;الوذمة) السوائل الزائدة في أنسجة الجسم، مما يسبب التورم (وقد تعرض بعض المرضى لنوبة قلبية أو سكتة دماغية أو</p><p dir="RTL">&nbsp;&raquo; ضربة صغيرة &laquo;أثناء تلقي بيميتريكسيد للحقن عادةً بالاشتراك مع علاج آخر مضاد للسرطان.</p><p dir="RTL">&bull;قلة الكريات الشاملة- الجمع بين انخفاض في الخلايا البيضاء والخلايا الحمراء والصفائح الدموية.</p><p dir="RTL">&bull;قد يحدث الالتهاب الرئوي الإشعاعي) تندب الأكياس الهوائية للرئة المرتبطة بالعلاج الإشعاعي (في المرضى الذين يعالجون أيضًا بالإشعاع قبل أو أثناء أو بعد العلاج مع بيميتريكسيد للحقن.</p><p dir="RTL">&bull; تم الإبلاغ عن حدوث ألم في الاطراف، درجة حرارة منخفضة و تغير اللون.</p><p dir="RTL">&bull;جلطات الدم في الأوعية الدموية الرئوية) انسداد رئوي (.</p><p dir="RTL">نادرة )قد تؤثر على 1 من كل 1000 شخص(</p><p dir="RTL">&bull;الاسترجاع الإشعاعي) طفح جلدي مثل حروق الشمس الحادة (الذي يمكن أن يحدث على الجلد الذي سبق أن تعرض للعلاج الإشعاعي، من أيام إلى سنوات بعد الإشعاع.</p><p dir="RTL">&bull;الحالات الفقاعية) أمراض الجلد المتقرحة (، بما في ذلك متلازمة ستيفنز جونسون وانحلال البشرة</p><p dir="RTL">النخري السمي.</p><p dir="RTL">&bull;فقر الدم الانحلالي بسبب مناعي) تدمير بواسطة الأجسام المضادة لخلايا الدم الحمراء (.</p><p dir="RTL">&bull;التهاب الكبد.</p><p dir="RTL">&bull;صدمة تحسسية) رد فعل تحسسي شديد (.</p><p dir="RTL">غير معروفة: لا يمكن تقدير تكرارها من البيانات المتاحة</p><p dir="RTL">&bull;تورم الطرف السفلي مع ألم واحمرار</p><p dir="RTL">&bull;زيادة افراز البول</p><p dir="RTL">&bull;العطش وزيادة استهلاك المياه</p><p dir="RTL">&bull;فرط صوديوم الدم - زيادة الصوديوم في الدم</p><p dir="RTL">قد يكون لديك أي من هذه الأعراض و / أو الحالات. يجب عليك إخبار طبيبك في أقرب وقت ممكن</p><p dir="RTL">عندما تبدأ في مواجهة أي من هذه الآثار الجانبية.</p><p dir="RTL">إذا كنت قلقًا بشأن أي آثر جانبي، تحدث إلى طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&bull;يحفظ هذا الدواء بعيدًا عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور علي الملصق و الكرتونة.</p><p dir="RTL">&bull; هذا الدواء لا يتطلب أي شروط تخزين خاصة.</p><p dir="RTL">&bull;حلّ ومحلول التسريب: يجب استخدام المنتج على الفور. عندما تم تحضيره على النحو الموجه، تم</p><p dir="RTL">إثبات الاستقرار الكيميائي والفيزيائي في الاستخدام للمحلول المعد من بيميتريكسيد لمدة 24 ساعة في درجة حرارة 2-8 درجات مئوية.</p><p dir="RTL">&bull;هذا الدواء للاستخدام الفردي فقط ؛ يجب التخلص من أي محلول غير مستخدم وفقا للمتطلبات المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على</strong><strong> </strong><strong>ماذا</strong><strong> </strong><strong>يحتوي</strong><strong> </strong><strong>الميترا</strong></p><p dir="RTL">المادة الفعالة هي بيميتريكسيد.</p><p dir="RTL"><strong>الميترا</strong><strong> 500 </strong><strong>ملغم</strong><strong>: </strong>تحتوي كل قنينة على 500 ملغم من بيميتريكسيد )على هيئة ثنائي الصوديوم).</p><p dir="RTL">بعد الحلّ، يحتوي المحلول على 25 ملغم / مل من بيميتريكسيد.</p><p dir="RTL">يطلب تخفيفه أكثر من قبل مقدم الرعاية الصحية قبل الإعطاء.</p><p dir="RTL">المكونات الأخرى هي المانيتول وحمض الهيدروكلوريك وهيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الميترا</strong><strong> </strong>هو مسحوق مركز في قارورة للحلّ والاعطاء عن طريق التسريب للتسريب. وهو عبارة عن مادة صلبة مجففة بالتجميد ذات لون أبيض أو بيج في قارورة عديمة اللون مع سدادة مطاطية رمادية وختم من الألومنيوم.</p><p dir="RTL">كل عبوة من <strong>الميترا</strong><strong> </strong>تتكون من قنينة واحدة.</p><p dir="RTL">لقد لا تسوق جميع أحجام العبوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المعلومات</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>مخصصة</strong><strong> </strong><strong>للمتخصصين</strong><strong> </strong><strong>في</strong><strong> </strong><strong>المجال</strong><strong> </strong><strong>الطبي</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الرعاية</strong><strong> </strong><strong>الصحية</strong><strong> </strong><strong>فقط</strong></p><p dir="RTL">تعليمات للاستخدام والتعامل والتخلص.</p><p dir="RTL">1. يجب استخدام تقنيات التعقيم خلال الحلّ ويجب تخفيف <strong>الميترا</strong><strong> </strong>أكثر قبل تسريبه في الوريد.</p><p dir="RTL">2. يجب حساب الجرعة وعدد قوارير <strong>الميترا</strong><strong> </strong>اللازمة للحقن. تحتوي كل قارورة على فائض من</p><p dir="RTL"><strong>الميترا</strong><strong> </strong>لتسهيل اعطاء الكمية المطلوبة.</p><p dir="RTL">3. <strong>الميترا</strong><strong> </strong>500 ملغم:</p><p dir="RTL">يجب حل كل قارورة سعة 500 ملغم مع 20 مل من محلول كلوريد الصوديوم (0.9%)(0.9%) للحقن ، بدون مواد حافظة، مما ينتج عنه محلول يحتوي علي 25 ملغم / مل بيميتريكسيد.</p><p dir="RTL">قم بتدوير كل قنينة برفق حتي يذوب المسحوق تماماً. المحلول الناتج شفاف ويتراوح في اللون من عديم اللون إلي أصفر أو أخضر مصفر دون التأثير سلبا علي جودة المنتج. ويتراوح الأس الهيدروجيني للمحلول المعد بين 6,6 و 7,8. يطلب مزيد من التخفيف.</p><p dir="RTL">4. يجب تخفيف الكمية المناسبة من محلول <strong>الميترا</strong><strong> </strong>المعد إلى 100 مل مع محلول كلوريد</p><p dir="RTL">الصوديوم 9 ملغم / مل( 0.9 ٪ ) للحقن، بدون مواد حافظة، ويتم إعطاؤه بالتسريب الوريدي على</p><p dir="RTL">مدى 10 دقائق.</p><p dir="RTL">5. محاليل التسريب <strong>الميترا</strong><strong> </strong>المعدة حسب التوجيهات أعلاه متوافقة مع مجموعات الإعطاء و أكياس</p><p dir="RTL">الحقن المبطنة بمادة بولي فينيل كلوريد و البوليفين. بيميتريكسيد غير متوافق مع المواد المخففة التي تحتوي على الكالسيوم، بما في ذلك محلول رينجر لاكتات و محلول رينجر.</p><p dir="RTL">6. يجب فحص المنتجات الطبية المعدة للحقن بصريا لوجود جسيمات وتغير في اللون قبل الإعطاءة.</p><p dir="RTL">إذا لوحظ الجسيمات، يجب عدم استعمالها.</p><p dir="RTL">7. &nbsp;محلول <strong>الميترا</strong><strong> </strong>للاستخدام الفردي فقط. يجب التخلص من أي منتج أو نفايات غير مستخدمة</p><p dir="RTL">وفقًا للمتطلبات المحلية.</p><p dir="RTL"><strong>احتياطات</strong><strong> </strong><strong>التحضير</strong><strong> </strong><strong>والإعطاء</strong><strong>: </strong>كما هو الحال مع ادوية السرطان السامة الأخرى، يجب توخي الحذر</p><p dir="RTL">في استخدام وإعداد محلول تسريب <strong>الميترا</strong><strong> </strong>. من المستحسن استخدام قفازات. إذا وصل محلول</p><p dir="RTL"><strong>الميترا</strong><strong> </strong>للجلد، فقم بغسل الجلد على الفور وبدقة بالماء والصابون. إذا وصلت محاليل بيميتريكسيد</p><p dir="RTL">بالأغشية المخاطية، فقم بتدفق كامل للماء. بيميتريكسيد ليس مولد للبثور الجلدية. لا يوجد ترياق محدد</p><p dir="RTL">لانصباب بيميتريكسيد الدموي. كان هناك عدد قليل من الحالات المبلغ عنها لانصباب بيميتريكسيد الدموي، والتي لم يتم تقييمها على أنها خطيرة من قبل المحقق. يجب علاج الانصباب الدموي وفقا للممارسة القياسية المحلية كما هو الحال مع المواد الأخرى غير المسببة للبثور.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يصنع بواسطة</strong></p><p dir="RTL">مجموعة جانسو هانسو الصيدلانية المحدودة &ndash; جانسو &ndash; الصين لصالح إم إس فارما &ndash; المملكة العربية السعودية</p><p dir="RTL"><strong>اسم و عنوان مالك رخصة التسويق</strong></p><p dir="RTL">إم إس فارما السعودية الرياض ، المملكة العربية السعودية .</p><p dir="RTL">البريد الالكتروني: info-ksa@mspharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو ، 2021

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Almetra® 500 mg powder for concentrate for solution for infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 500 mg of pemetrexed (as pemetrexed disodium). 
After reconstitution (see section 6.6), each vial contains 25 mg/ml of pemetrexed.  
Excipients with known effect: Each vial contains less than 2.34 mmol (54 mg) of sodium. 
For the full list of excipients see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion. 
White to off-white lyophilized powder 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Malignant pleural mesothelioma</p><p><strong>Almetra<sup>&reg;</sup></strong> in combination with cisplatin is indicated for the treatment of chemotherapy na&iuml;ve patients with unresectable malignant pleural mesothelioma. <u>Non-small cell lung cancer</u></p><p><strong>Almetra<sup>&reg;</sup></strong> in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).</p><p><strong>Almetra<sup>&reg;</sup></strong> is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).</p><p><strong>Almetra<sup>&reg;</sup></strong> is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology:</u></p><p><strong>Almetra<sup>&reg;</sup></strong> must only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.</p><p>Almetra<sup>&reg;</sup> in combination with cisplatin</p><p>The recommended dose of <strong>Almetra<sup>&reg;</sup></strong> is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 BSA infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle. <u>Patients must receive adequate anti-emetic</u> <u>treatment and appropriate hydration prior to and/or after receiving cisplatin</u> (see also cisplatin Summary of Product Characteristics for specific dosing advice).</p><p>Almetra<sup>&reg;</sup> as single agent</p><p>In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Almetra<sup>&reg;</sup><sub> </sub>is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.</p><p>Premedication regimen</p><p>To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration. The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day (see section 4.4).</p><p>To reduce toxicity, patients treated with pemetrexed must also receive vitamin supplementation (see section 4.4). Patients must take oral folic acid or a multivitamin containing folic acid (350 to 1000 micrograms) on a daily basis. At least five doses of folic acid must be taken during the seven days preceding the first dose of pemetrexed, and dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed. Patients must also receive an intramuscular injection of Vitamin B12 (1000 micrograms) in the week preceding the first dose of pemetrexed and once every three cycles thereafter. Subsequent Vitamin B12 injections may be given on the same day as pemetrexed. <u>Monitoring</u></p><p>Patients receiving pemetrexed should be monitored before each dose with a complete blood count, including a differential white cell count (WCC) and platelet count. Prior to each chemotherapy administration blood chemistry tests should be collected to evaluate renal and hepatic function. Before the start of any cycle of chemotherapy, patients are required to have the following: absolute neutrophil count (ANC) should be &ge; 1500 cells/mm3 and platelets should be &ge; 100,000 cells/mm3.</p><p>Creatinine clearance should be &ge; 45 ml/min.</p><p>The total bilirubin should be &le; 1.5 times upper limit of normal. Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be &le; 3 times upper limit of normal. Alkaline phosphatase, AST and ALT &le; 5 times upper limit of normal is acceptable if liver has tumour involvement.</p><p>Dose adjustments</p><p>Dose adjustments at the start of a subsequent cycle should be based on nadir haematologic counts or maximum non-haematologic toxicity from the preceding cycle of therapy. Treatment may be delayed to allow sufficient time for recovery. Upon recovery patients should be retreated using the guidelines in <strong><em>Tables 1, 2 and 3</em></strong>, which are applicable for <sub>Almetra</sub><sup>&reg; </sup>used as a single agent or in combination with cisplatin.</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 1 - Dose modification table for Almetra<sup>&reg; </sup>(as single agent or in combination) and cisplatin &ndash;</strong></p><p><strong>Haematologic toxicities</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nadir ANC &lt; 500 /mm<sup>3</sup> and nadir platelets &ge; 50,000 /mm<sup>3</sup></p></td><td style="vertical-align:top"><p>75 % of previous dose (both Almetra<sup>&reg;</sup> and cisplatin)</p></td></tr><tr><td style="vertical-align:top"><p>Nadir platelets &lt; 50,000 /mm<sup>3</sup> regardless of nadir</p><p>ANC</p></td><td style="vertical-align:top"><p>75 % of previous dose (both Almetra<sup>&reg;</sup> and cisplatin )</p></td></tr><tr><td style="vertical-align:top"><p>Nadir platelets &lt; 50,000 /mm<sup>3</sup> with bleeding<sup>a,</sup> regardless of nadir ANC</p></td><td style="vertical-align:top"><p>50 % of previous dose (both Almetra<sup>&reg; </sup>and cisplatin)</p></td></tr></tbody></table><p><sup>a</sup>These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of &ge;CTC Grade 2 bleeding.</p><p>If patients develop non-haematologic toxicities &ge; Grade 3 (excluding neurotoxicity), Almetra<sup>&reg;</sup> should be withheld until resolution to less than or equal to the patient&#39;s pre-therapy value.</p><p>Treatment should be resumed according to the guidelines in <strong><em>Table 2</em></strong>.</p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 2 - Dose modification table for Almetra<sup>&reg; </sup>(as single agent or in combination) and cisplatin&ndash; </strong></p><p><strong>Non-haematologic toxicities<sup>a, b</sup></strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose of Almetra<sup>&reg;</sup> </strong></p><p><strong>(mg/m<sup>2</sup>)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose for cisplatin</strong></p><p><strong>(mg/m<sup>2</sup>)</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Any Grade 3 or 4 toxicities except mucositis</p></td><td style="vertical-align:top"><p>75 % of previous dose</p></td><td style="vertical-align:top"><p>75 % of previous dose</p></td></tr><tr><td style="vertical-align:top"><p>Any diarrhoea requiring hospitalisation</p><p>(irrespective of grade) or grade 3 or 4 diarrhoea.</p></td><td style="vertical-align:top"><p>75 % of previous dose</p></td><td style="vertical-align:top"><p>75 % of previous dose</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3 or 4 mucositis</p></td><td style="vertical-align:top"><p>50 % of previous dose</p></td><td style="vertical-align:top"><p>100 % of previous dose</p></td></tr></tbody></table><p><sup>a </sup>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) <sup>b </sup>Excluding neurotoxicity</p><p>In the event of neurotoxicity, the recommended dose adjustment for <sub>Almetra</sub><sup>&reg;</sup> and cisplatin is documented in <strong><em>Table 3</em></strong>. Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is observed.</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 3 - Dose modification table for Almetra<sup>&reg;</sup> (as single agent or in combination) and cisplatin &ndash; </strong></p><p><strong>Neurotoxicity</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>CTC<sup>a</sup> Grade</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose of Pemetrexed (mg/m<sup>2</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Dose for cisplatin (mg/m<sup>2</sup>)</strong></p></td></tr><tr><td style="vertical-align:top"><p>0 &ndash; 1</p></td><td style="vertical-align:top"><p>100 % of previous dose</p></td><td style="vertical-align:top"><p>100 % of previous dose</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>100 % of previous dose</p></td><td style="vertical-align:top"><p>50 % of previous dose</p></td></tr></tbody></table><p><sup>a </sup>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998)</p><p>Treatment with <strong>Almetra<sup>&reg;</sup></strong> should be discontinued if a patient experiences any haematologic or nonhaematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.</p><p>Elderly: In clinical studies, there has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. No dose reductions other than those recommended for all patients are necessary.</p><p><em>Paediatric population</em></p><p>There is no relevant use of <strong>Almetra<sup>&reg;</sup></strong> in the paediatric population in malignant pleural mesothelioma and non-small cell lung cancer.</p><p><em>Patients with renal impairment: </em>(Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): <sub>Almetra</sub><sup>&reg;</sup> is primarily eliminated unchanged by renal excretion. In clinical studies, patients with creatinine clearance of &ge; 45 ml/min required no dose adjustments other than those recommended for all patients. There are insufficient data on the use of pemetrexed in patients with creatinine clearance below 45 ml/min; therefore the use of pemetrexed is not recommended (see section 4.4).</p><p><em>Patients with hepatic impairment: </em>No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified. However patients with hepatic impairment such as bilirubin &gt; 1.5 times the upper limit of normal and/or aminotransferase &gt; 3.0 times the upper limit of normal (hepatic metastases absent) or &gt; 5.0 times the upper limit of normal (hepatic metastases present) have not been specifically studied.</p><p><u>Method of administration:</u></p><p>For Precautions to be taken before handling or administering <strong>Almetra<sup>&reg;</sup></strong>, see section 6.6.</p><p><strong>Almetra<sup>&reg;</sup></strong>, a clear, colorless to yellow or yellow-green colored solution, once reconstituted; should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. For instructions on reconstitution and dilution of <strong>Almetra<sup>&reg;</sup></strong> before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Breast-feeding (see section 4.6).
•	Concomitant yellow fever vaccine (see section 4.5)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia and anaemia (or pancytopenia) (see section 4.8). Myelosuppression is usually the dose-limiting toxicity. Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to &ge; 1500 cells/mm3 and platelet</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_76460" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:461.25pt;height:25.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="615" height="34" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>section 4.2).</p><p>Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities such as neutropenia, febrile neutropenia and infection with Grade 3/4 neutropenia were reported when pretreatment with folic acid and Vitamin B12 was administered. Therefore, all patients treated with pemetrexed must be instructed to take folic acid and Vitamin B12 as a prophylactic measure to reduce treatment-related toxicity (see section 4.2).</p><p>Skin reactions have been reported in patients not pre-treated with a corticosteroid. Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and severity of skin reactions (see section 4.2).</p><p>An insufficient number of patients has been studied with creatinine clearance of below 45 ml/min. Therefore, the use of pemetrexed in patients with creatinine clearance of &lt; 45 ml/min is not recommended (see section 4.2).</p><p>Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, and aspirin (&gt; 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).&nbsp;</p><p>In patients with mild to moderate renal insufficiency eligible for pemetrexed therapy NSAIDs with long elimination half-lives should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.5).</p><p>Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents. Many of the patients in whom these occurred had underlying risk factors for the development of renal events including dehydration or pre-existing hypertension or diabetes. Nephrogenic diabetes insipidus and renal tubular necrosis were also reported in post marketing setting with pemetrexed alone or with other chemotherapeutic agents. Most of these events resolved after pemetrexed withdrawal. Patients should be regularly monitored for acute tubular necrosis, decreased renal function and signs and symptoms of nephrogenic diabetes insipidus (e.g. hypernatraemia)</p><p>The effect of third space fluid, such as pleural effusion or ascites, on pemetrexed is not fully defined. A phase 2 study of pemetrexed in 31 solid tumour patients with stable third space fluid demonstrated no difference in pemetrexed dose normalized plasma concentrations or clearance compared to patients without third space fluid collections. Thus, drainage of third space fluid collection prior to pemetrexed treatment should be considered, but may not be necessary.</p><p>Due to the gastrointestinal toxicity of pemetrexed given in combination with cisplatin, severe dehydration has been observed. Therefore, patients should receive adequate antiemetic treatment and appropriate hydration prior to and/or after receiving treatment.</p><p>Serious cardiovascular events, including myocardial infarction and cerebrovascular events have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. Most of the patients in whom these events have been observed had pre- existing cardiovascular risk factors (see section 4.8).</p><p>Immunodepressed status is common in cancer patients. As a result, concomitant use of live attenuated vaccines is not recommended (see section 4.3 and 4.5).</p><p>Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter. Contraceptive measures or abstinence are recommended. Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.</p><p>Women of childbearing potential must use effective contraception during treatment with pemetrexed (see section 4.6).</p><p>Cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy. Particular attention should be paid to these patients and caution exercised with use of other radiosensitising agents.</p><p>Cases of radiation recall have been reported in patients who received radiotherapy weeks or years previously.</p><p>This medicinal product contains approximately 2.35 mmol (54 mg) sodium per vial. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed is mainly eliminated unchanged renally by tubular secretion and to a lesser extent by glomerular filtration. Concomitant administration of nephrotoxic drugs (e.g. aminoglycoside, loop diuretics, platinum compounds, cyclosporin) could potentially result in delayed clearance of pemetrexed. This combination should be used with caution. If necessary, creatinine clearance should be closely monitored.</p><p>Concomitant administration of substances that are also tubularly secreted (e.g. probenecid, penicillin) could potentially result in delayed clearance of pemetrexed. Caution should be made when these drugs are combined with pemetrexed. If necessary, creatinine clearance should be closely monitored.</p><p>In patients with normal renal function (creatinine clearance &gt; 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and aspirin at higher dose (&gt; 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events. Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance &gt; 80 ml/min).</p><p>In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or aspirin at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).</p><p>In the absence of data regarding potential interaction with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.4). If concomitant administration of NSAIDs is necessary, patients should be monitored closely for toxicity, especially myelosuppression and gastrointestinal toxicity.</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_1246" o:spid="_x0000_i1028" type="#_x0000_t75"
   style='width:129pt;height:38.25pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="172" height="51" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /><strong>&nbsp;</strong></p></td><td><p><strong>Summary of Product Characteristics</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Almetra<sup>&reg;</sup> </strong><strong>500 mg powder for concentrate for solution for infusion</strong><strong> </strong></p></td></tr></tbody></table><p>&nbsp;</p><p>Pemetrexed undergoes limited hepatic metabolism. Results from in vitro studies with human liver microsomes indicated that pemetrexed would not be predicted to cause clinically significant inhibition of the metabolic clearance of drugs metabolised by CYP3A, CYP2D6, CYP2C9, and CYP1A2.</p><p><u>Interactions common to all cytotoxics:</u>&nbsp;</p><p>Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation treatment is frequent. The high intra-individual variability of the coagulation status during diseases and the possibility of interaction between oral anticoagulants and anticancer chemotherapy require increased frequency of INR (International Normalised Ratio) monitoring, if it is decided to treat the patient with oral anticoagulants.</p><p><u>Concomitant use contraindicated:</u>&nbsp;</p><p>Yellow fever vaccine: risk of fatal generalised vaccinale disease (see section 4.3).</p><p><u>Concomitant use not recommended:</u>&nbsp;</p><p>Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease. The risk is increased in subjects who are already immunosuppressed by their underlying disease. Use an inactivated vaccine where it exists (poliomyelitis) (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Contraception in males and females&nbsp;</p><p>Women of childbearing potential must use effective contraception during treatment with pemetrexed. Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter. Contraceptive measures or abstinence are recommended.</p><p>&nbsp;</p><p>Pregnancy&nbsp;</p><p>There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other antimetabolites, is suspected to cause serious birth defects when administered during pregnancy. Animal studies have shown reproductive toxicity (see section 5.3). Pemetrexed should not be used during pregnancy unless clearly necessary, after a careful consideration of the needs of the mother and the risk for the foetus (see section 4.4). <u>Breastfeeding</u></p><p>It is not known whether pemetrexed is excreted in human milk and adverse reactions on the suckling child cannot be excluded. Breast-feeding must be discontinued during pemetrexed therapy (see section 4.3).</p><p>Fertility</p><p>Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, it has been reported that pemetrexed may cause fatigue. Therefore patients should be cautioned against driving or operating machines if this event occurs.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Summary of the safety profile</em></strong><strong> </strong></p><p>The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and Toxic epidermal necrolysis.</p><p><strong><em>Tabulated list of adverse reactions</em></strong><strong> </strong></p><p>The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin. In both treatment arms, these chemonaive patients were fully supplemented with folic acid and Vitamin B<sub>12</sub>.</p><p><em>Adverse reactions</em></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_76461" o:spid="_x0000_i1029" type="#_x0000_t75"
 style='width:484.5pt;height:25.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="646" height="34" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>from available data-spontaneous reports).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td rowspan="3"><p><strong>System Organ class</strong></p></td><td rowspan="3"><p><strong>Frequency</strong></p></td><td rowspan="3"><p><strong>Event*</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Pemetrexed/cisplatin</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Cisplatin</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>(N = 168)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>(N = 163)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All grades toxicity</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 - 4 toxicity</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>All grades toxicity</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 </strong></p><p><strong>- 4</strong></p><p><strong>toxicity</strong></p><p><strong>(%)</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Neutrophils/ Granulocytes decreased</p></td><td><p>56.0</p></td><td><p>23.2</p></td><td><p>13.5</p></td><td><p>3.1</p></td></tr><tr><td style="vertical-align:top"><p>Leukocytes decreased</p></td><td><p>53.0</p></td><td><p>14.9</p></td><td><p>16.6</p></td><td><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin decreased</p></td><td><p>26.2</p></td><td><p>4.2</p></td><td><p>10.4</p></td><td><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Platelets decreased</p></td><td style="vertical-align:top"><p>23.2</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>Dehydration</p></td><td><p>6.5</p></td><td><p>4.2</p></td><td><p>0.6</p></td><td><p>0.6</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>Neuropathy- Sensory</p></td><td><p>10.1</p></td><td><p>0.0</p></td><td><p>9.8</p></td><td><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Taste disturbance</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>0.0***</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>0.0***</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="6" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>56.5</p></td><td style="vertical-align:top"><p>10.7</p></td><td style="vertical-align:top"><p>49.7</p></td><td style="vertical-align:top"><p>4.3</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis/ Pharyngitis</p></td><td><p>23.2</p></td><td><p>3.0</p></td><td><p>6.1</p></td><td><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>82.1</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>76.7</p></td><td style="vertical-align:top"><p>5.5</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>20.2</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>14.1</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>16.1</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td><p>Alopecia</p></td><td><p>11.3</p></td><td><p>0.0***</p></td><td><p>5.5</p></td><td><p>0.0***</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Creatinine elevation</p></td><td style="vertical-align:top"><p>10.7</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>9.8</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance decreased**</p></td><td><p>16.1</p></td><td><p>0.6</p></td><td><p>17.8</p></td><td><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>Fatigue</p></td><td><p>47.6</p></td><td><p>10.1</p></td><td><p>42.3</p></td><td><p>9.2</p></td></tr></tbody></table><p>* Refer to National Cancer Institute CTC version 2 for each grade of toxicity except the term &ldquo;creatinine clearance decreased&rdquo;</p><p>** which is derived from the term &ldquo;renal/genitourinary other&rdquo;.</p><p>*** According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.</p><p>For the purpose of this table a cut off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_76462" o:spid="_x0000_i1028"
 type="#_x0000_t75" style='width:467.25pt;height:39pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="623" height="52" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.</p><p>The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 265 patients randomly assigned to receive single agent pemetrexed with folic acid and</p><p>Vitamin B12 supplementation and 276 patients randomly assigned to receive single agent docetaxel. All patients were diagnosed with locally advanced or metastatic non-small cell lung cancer and received prior chemotherapy.</p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td rowspan="2"><p><strong>System organclass</strong></p></td><td rowspan="2"><p><strong>Frequency</strong></p></td><td rowspan="2"><p><strong>Event*</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Pemetrexed</strong></p><p><strong>N = 265</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Docetaxel</strong></p><p><strong>N = 276</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All grades toxicity</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 &ndash; </strong></p><p><strong>4 toxicity</strong> <strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>All Grades toxicity</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade </strong></p><p><strong>3 &ndash; 4 toxicity</strong></p><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p></td><td style="vertical-align:top"><p>Very</p><p>Common</p></td><td style="vertical-align:top"><p>Neutrophils/</p><p>Granulocytes decreased</p></td><td><p>10.9</p></td><td><p>5.3</p></td><td><p>45.3</p></td><td><p>40.2</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>disorders</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukocytes decreased</p></td><td style="vertical-align:top"><p>12.1</p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>34.1</p></td><td style="vertical-align:top"><p>27.2</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin decreased</p></td><td><p>19.2</p></td><td><p>4.2</p></td><td><p>22.1</p></td><td><p>4.3</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Platelets decreased</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="5" style="vertical-align:top"><p>Very</p><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>24.3</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>16.2</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>12.0</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis/Pharyngitis</p></td><td style="vertical-align:top"><p>14.7</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>17.4</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>30.9</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>21.9</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>23.9</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>SGPT (ALT) elevation</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>SGOT (AST) elevation</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and sub- cutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very</p><p>Common</p></td><td style="vertical-align:top"><p>Rash/ desquamation</p></td><td><p>14.0</p></td><td><p>0.0</p></td><td><p>6.2</p></td><td><p>0.0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>0.4**</p></td><td style="vertical-align:top"><p>37.7</p></td><td style="vertical-align:top"><p>2.2**</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very</p><p>Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td><p>34.0</p></td><td><p>5.3</p></td><td><p>35.9</p></td><td><p>5.4</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>0.0</p></td></tr></tbody></table><p>*Refer to National Cancer Institute CTC version 2 for each grade of toxicity.</p><p>**According to National Cancer Institute CTC (v2.0; NCI 1998), alopecia should only be reported as Grade 1 or 2.</p><p>For the purpose of this table a cut off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.</p><p>Clinically relevant CTC toxicities that were reported in &ge; 1 % and &lt; 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction / hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.</p><p>Clinically relevant CTC toxicities that were reported in &lt; 1 % of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.</p><p>Clinically relevant Grade 3 and Grade 4 laboratory toxicities were similar between integrated Phase 2 results from three single agent pemetrexed studies (n = 164) and the Phase 3 single agent pemetrexed study described above, with the exception of neutropenia (12.8 % versus 5.3 %, respectively) and alanine aminotransferase elevation (15.2 % versus 1.9 %, respectively). These differences were likely due to differences in the patient population, since the Phase 2 studies included both chemonaive and heavily pre-treated breast cancer patients with pre-existing liver metastases and/or abnormal baseline liver function tests.</p><p>The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &gt;5% of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine. All patients received study therapy as initial treatment for locally advanced or metastatic NSCLC and patients in both treatment groups were fully supplemented with folic acid and Vitamin B<sub>12</sub>.</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td rowspan="2"><p><strong>System organ </strong></p><p><strong>class</strong>&nbsp;</p></td><td rowspan="2"><p><strong>Frequency</strong></p></td><td rowspan="2"><p><strong>Event**</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Pemetrexed/cisplatin</strong></p><p><strong>(N = 839)</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine/cisplatin</strong></p><p><strong>(N = 830)</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>All grades toxicity </strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 - 4 toxicity (%)</strong></p></td><td style="vertical-align:top"><p><strong>All grades toxicity </strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 - 4 toxicity (%)</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>33.0*</p></td><td style="vertical-align:top"><p>5.6*</p></td><td style="vertical-align:top"><p>45.7*</p></td><td style="vertical-align:top"><p>9.9*</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophils/ Granulocytes decreased</p></td><td style="vertical-align:top"><p>29.0*</p></td><td style="vertical-align:top"><p>15.1*</p></td><td style="vertical-align:top"><p>38.4*</p></td><td style="vertical-align:top"><p>26.7*</p></td></tr><tr><td style="vertical-align:top"><p>Leukocytes Decreased</p></td><td style="vertical-align:top"><p>17.8</p></td><td style="vertical-align:top"><p>4.8*</p></td><td style="vertical-align:top"><p>20.6</p></td><td style="vertical-align:top"><p>7.6*</p></td></tr><tr><td style="vertical-align:top"><p>Platelets Decreased</p></td><td style="vertical-align:top"><p>10.1*</p></td><td style="vertical-align:top"><p>4.1*</p></td><td style="vertical-align:top"><p>26.6*</p></td><td style="vertical-align:top"><p>12.7*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Neuropathy-sensory</p></td><td style="vertical-align:top"><p>8.5*</p></td><td style="vertical-align:top"><p>0.0*</p></td><td style="vertical-align:top"><p>12.4*</p></td><td style="vertical-align:top"><p>0.6*</p></td></tr><tr><td style="vertical-align:top"><p>Taste disturbance</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>0.0***</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>0.0***</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="6" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>56.1</p></td><td style="vertical-align:top"><p>7.2*</p></td><td style="vertical-align:top"><p>53.4</p></td><td style="vertical-align:top"><p>3.9*</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>39.7</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>35.5</p></td><td style="vertical-align:top"><p>6.1</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>26.6</p></td><td style="vertical-align:top"><p>2.4*</p></td><td style="vertical-align:top"><p>24.2</p></td><td style="vertical-align:top"><p>0.7*</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>21.0</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>19.5</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis/ Pharyngitis</p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>12.4</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea without colostomy</p></td><td style="vertical-align:top"><p>12.4</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspepsia/ Heartburn</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p></td><td style="vertical-align:top"><p>Very</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>11.9*</p></td><td style="vertical-align:top"><p>0***</p></td><td style="vertical-align:top"><p>21.4*</p></td><td style="vertical-align:top"><p>0.5***</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash/desquamation</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Creatinine elevation</p></td><td style="vertical-align:top"><p>10.1*</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>6.9*</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>42.7</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>44.9</p></td><td style="vertical-align:top"><p>4.9</p></td></tr></tbody></table><p>*P-values &lt;0.05 comparing pemetrexed/cisplatin to gemcitabine/cisplatin, using Fisher Exact test. **Refer to National Cancer Institute CTC (v2.0; NCI 1998) for each Grade of Toxicity.</p><p>***According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.</p><p>For the purpose of this table, a cut-off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_76463" o:spid="_x0000_i1027"
 type="#_x0000_t75" style='width:481.5pt;height:66.75pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="642" height="89" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /></p><p>neuropathy.</p><p>Clinically relevant toxicities with respect to gender were similar to the overall population in patients receiving pemetrexed plus cisplatin.</p><p>The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &gt; 5% of 800 patients randomly assigned to receive single agent pemetrexed and 402 patients randomly assigned to receive placebo in the single-agent pemetrexed maintenance (JMEN: N= 663) and continuation pemetrexed maintenance</p><p>(PARAMOUNT: N=539) studies. All patients were diagnosed with Stage IIIB or IV NSCLC and had received prior platinum-based chemotherapy. Patients in both study arms were fully supplemented with folic acid and Vitamin B<sub>12</sub>.</p><table border="0" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td rowspan="2"><p><strong>System organ class</strong></p></td><td rowspan="2"><p><strong>Frequency*</strong></p></td><td rowspan="2"><p><strong>Event**</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Pemetrexed*** </strong></p><p><strong>(N =800)</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo*** </strong></p><p><strong>N =402)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All </strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 - 4 </strong></p></td><td style="vertical-align:top"><p><strong>All grades </strong></p></td><td style="vertical-align:top"><p><strong>Grade </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>grades </strong></p><p><strong>toxicity </strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>toxicity (%)</strong></p></td><td style="vertical-align:top"><p><strong>toxicity (%)</strong></p></td><td style="vertical-align:top"><p><strong>3 - 4 toxicity</strong></p><p><strong>(%)</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>18.0</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Leukocytes decreased</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophils decreased</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Neuropathy- sensory</p></td><td><p>7.4</p></td><td><p>0.6</p></td><td><p>5.0</p></td><td><p>0.2</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>17.3</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Mucositis/stomatitis</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>ALT (SGPT) elevation</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>AST (SGOT) elevation</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash/desquamation</p></td><td><p>8.1</p></td><td><p>0.1</p></td><td><p>3.7</p></td><td><p>0.0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>24.1</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>10.9</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Renal Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal disorders****</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0.0</p></td></tr></tbody></table><p>Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacectic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacectic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.</p><p>* Definition of frequency terms: Very common - &ge; 10%; Common - &gt; 5% and &lt; 10%. For the purpose of this table, a cutoff of 5% was used for inclusion of all events where the reporter<sub> </sub>considered a possible relationship to pemetrexed.</p><p>** Refer to NCI CTCAE Criteria (Version 3.0; NCI 2003) for each grade of toxicity. The reporting rates shown are according to CTCAE version 3.0.</p><p>*** Integrated adverse reactions table combines the results of the JMEN pemetrexed maintenance (N=663) and PARAMOUNT continuation pemetrexed maintenance (N=539) studies.</p><p>**** Combined term includes increased serum/blood creatinine, decreased glomerular filtration rate, renal failure and renal/genitourinary- other.</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_76464" o:spid="_x0000_i1026"
 type="#_x0000_t75" style='width:489pt;height:52.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
</v:shape><![endif]--><img width="652" height="70" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /></p><p>Clinically relevant CTC toxicity that was reported in &lt; 1% of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_76465" o:spid="_x0000_i1025"
 type="#_x0000_t75" style='width:489pt;height:94.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
  o:title=""/>
</v:shape><![endif]--><img width="652" height="126" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /></p><p>Serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident and transient ischaemic attack have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. Most of the patients in whom these events have been observed had pre-existing cardiovascular risk factors.</p><p>Rare cases of hepatitis, potentially serious, have been reported during clinical studies with pemetrexed.&nbsp;</p><p>Pancytopenia has been uncommonly reported during clinical trials with pemetrexed.</p><p>In clinical trials, cases of colitis (including intestinal and rectal bleeding, sometimes fatal, intestinal perforation, intestinal necrosis and typhlitis) have been reported uncommonly in patients treated with pemetrexed.</p><p>In clinical trials, cases of interstitial pneumonitis with respiratory insufficiency, sometimes fatal, have been reported uncommonly in patients treated with pemetrexed.</p><p>Uncommon cases of oedema have been reported in patients treated with pemetrexed.</p><p>Oesophagitis/ radiation oesophagitis has been uncommonly reported during clinical trials with pemetrexed.</p><p>Sepsis, sometimes fatal, has been commonly reported during clinical trials with pemetrexed.</p><p>During post marketing surveillance, the following adverse reactions have been reported in patients treated with pemetrexed: Hyperpigmentation has been commonly reported.</p><p>Uncommon cases of acute renal failure have been reported with pemetrexed alone or in association with other chemotherapeutic agents (see section 4.4).</p><p>Uncommon cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy (see section 4.4).</p><p>Rare cases of radiation recall have been reported in patients who have received radiotherapy previously (see section 4.4).</p><p>Uncommon cases of peripheral ischaemia leading sometimes to extremity necrosis have been reported.&nbsp;</p><p>Rare cases of bullous conditions have been reported including Stevens-Johnson syndrome and Toxic epidermal necrolysis which in some cases were fatal.</p><p>Rarely, immune-mediated haemolytic anaemia has been reported in patients treated with pemetrexed. Rare cases of anaphylactic shock have been reported.</p><p>Erythematous oedema mainly of the lower limbs has been reported with an unknown frequency. Infectious and non-infectious disorders of the dermis, the hypodermis and/or the subcutaneous tissue have been reported with an unknown frequency (e.g. acute bacterial dermo-hypodermitis, pseudocellulitis, dermatitis).</p><p><u>Reporting of suspected adverse reactions</u>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions. <strong>To report any side effect(s): </strong></p><p>&bull; <strong>Saudi Arabia:</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p><strong>National Pharmacovigilance &amp; Drug Safety Centre (NPC):</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext. 2317-2356-2353-2354-2334-2340.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reported symptoms of overdose include neutropenia, anaemia, thrombocytopenia, mucositis, sensory polyneuropathy and rash. Anticipated complications of overdose include bone marrow suppression as manifested by neutropenia, thrombocytopenia and anaemia. In addition, infection with or without fever, diarrhoea, and/or mucositis may be seen. In the event of suspected overdose, patients should be monitored with blood counts and should receive supportive therapy as necessary. The use of calcium folinate / folinic acid in the management of pemetrexed overdose should be considered.<strong> </strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Folic acid analogues, ATC code: L01BA04</p><p><u>Mechanism of action</u></p><p><strong>Almetra<sup> &reg; </sup></strong>(pemetrexed) is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.</p><p><u>Pharmacodynamic effects</u></p><p>In vitro studies have shown that pemetrexed behaves as a multitargeted antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are key folate-dependent enzymes for the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are even more potent inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumour cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.</p><p><u>Clinical efficacy</u> <em><u>Mesothelioma:</u> </em></p><p>EMPHACIS, a multicentre, randomised, single-blind phase 3 study of <sub>Almetra</sub><sup>&reg;</sup> plus cisplatin versus cisplatin in chemonaive patients with malignant pleural mesothelioma, has shown that patients treated with <sub>Almetra</sub><sup>&reg;</sup> and cisplatin had a clinically meaningful 2.8-month median survival advantage over patients receiving cisplatin alone.</p><p>During the study, low-dose folic acid and Vitamin B12 supplementation was introduced to patients&#39; therapy to reduce toxicity. The primary analysis of this study was performed on the population of all patients randomly assigned to a treatment arm who received study drug (randomised and treated). A subgroup analysis was performed on patients who received folic acid and Vitamin B12 supplementation during the entire course of study therapy (fully supplemented). The results of these analyses of efficacy are summarised in the table below:</p><p>Efficacy of Pemetrexed plus cisplatin vs. cisplatin in Malignant pleural mesothelioma</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Randomized and treated patients</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Fully supplemented patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy parameter</strong></p></td><td style="vertical-align:top"><p><strong>Almetra<sup>&reg;</sup> / cisplatin</strong>&nbsp;</p><p><strong>(N = 226)</strong></p></td><td style="vertical-align:top"><p><strong>Cisplatin</strong> <strong>(N = 222)</strong></p></td><td style="vertical-align:top"><p><strong>Almetra<sup>&reg;</sup> / cisplatin</strong>&nbsp;</p><p><strong>(N = 168)</strong></p></td><td style="vertical-align:top"><p><strong>Cisplatin</strong> <strong>(N = 163)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median overall survival (months)</p><p>(95 % CI)</p></td><td style="vertical-align:top"><p>12.1</p><p>(10.0 - 14.4)</p></td><td style="vertical-align:top"><p>9.3</p><p>(7.8 - 10.7)</p></td><td style="vertical-align:top"><p>13.3</p><p>(11.4 - 14.9)</p></td><td style="vertical-align:top"><p>10.0</p><p>(8.4 - 11.9)</p></td></tr><tr><td style="vertical-align:top"><p>Log Rank p-value*</p></td><td colspan="2" style="vertical-align:top"><p>0.020</p></td><td colspan="2" style="vertical-align:top"><p>0.051</p></td></tr><tr><td style="vertical-align:top"><p>Median time to tumour progression</p><p>(months) (95 % CI)</p></td><td colspan="2"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_73581" o:spid="_x0000_s1030" style='position:absolute;
   left:0;text-align:left;margin-left:92.55pt;margin-top:-6.55pt;width:1.5pt;
   height:57.5pt;z-index:251671552;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="190,7299" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_79256" o:spid="_x0000_s1031" style='position:absolute;
    width:91;height:7299;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,729983" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,729983l,729983,,e" fillcolor="#f0f0f0" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,9144,729983"/>
   </v:shape><v:shape id="Shape_x0020_79257" o:spid="_x0000_s1032" style='position:absolute;
    left:99;width:91;height:7299;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,729983" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,729983l,729983,,e" fillcolor="#a1a1a1" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,9144,729983"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="2" height="77" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />5.7 3.9</p><p>(4.9 - 6.5) (2.8 - 4.4)</p></td><td colspan="2"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_73631" o:spid="_x0000_s1027" style='position:absolute;
   left:0;text-align:left;margin-left:102.95pt;margin-top:-6.55pt;width:1.45pt;
   height:57.5pt;z-index:251672576;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="182,7299" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_79260" o:spid="_x0000_s1028" style='position:absolute;
    width:91;height:7299;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,729983" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,729983l,729983,,e" fillcolor="#f0f0f0" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,9144,729983"/>
   </v:shape><v:shape id="Shape_x0020_79261" o:spid="_x0000_s1029" style='position:absolute;
    left:91;width:91;height:7299;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,729983" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,729983l,729983,,e" fillcolor="#a1a1a1" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,9144,729983"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="2" height="77" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />6.1 3.9</p><p>(5.3 - 7.0) (2.8 - 4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Log Rank p-value*</p></td><td colspan="2" style="vertical-align:top"><p>0.001</p></td><td colspan="2" style="vertical-align:top"><p>0.008</p></td></tr><tr><td style="vertical-align:top"><p>Time to treatment failure (months)</p><p>(95 % CI)</p></td><td style="vertical-align:top"><p>4.5</p><p>(3.9 - 4.9)</p></td><td style="vertical-align:top"><p>2.7</p><p>(2.1 - 2.9)</p></td><td style="vertical-align:top"><p>4.7</p><p>(4.3 - 5.6)</p></td><td style="vertical-align:top"><p>2.7</p><p>(2.2 - 3.1)</p></td></tr><tr><td style="vertical-align:top"><p>Log Rank p-value*</p></td><td colspan="2" style="vertical-align:top"><p>0.001</p></td><td colspan="2" style="vertical-align:top"><p>0.001</p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate**</p><p>(95 % CI)</p></td><td style="vertical-align:top"><p>41.3 % (34.8 - 48.1)</p></td><td style="vertical-align:top"><p>16.7 % (12.0 - 22.2)</p></td><td style="vertical-align:top"><p>45.5 % (37.8 - 53.4)</p></td><td style="vertical-align:top"><p>19.6 % (13.8 - 26.6)</p></td></tr><tr><td style="vertical-align:top"><p>Fisher&#39;s exact p-value*</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.001</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.001</p></td></tr></tbody></table><p>Abbreviation: CI = confidence interval</p><p>*<sub> </sub>p-value refers to comparison between arms.</p><p>** In the <sub>Almetra</sub><sup>&reg;</sup><sub> </sub>/cisplatin arm, randomized and treated (N = 225) and fully supplemented (N = 167)</p><p>A statistically significant improvement of the clinically relevant symptoms (pain and dyspnoea) associated with malignant pleural mesothelioma in the pemetrexed/cisplatin arm (212 patients) versus the cisplatin arm alone (218 patients) was demonstrated using the Lung Cancer Symptom Scale. Statistically significant differences in pulmonary function tests were also observed. The separation between the treatment arms was achieved by improvement in lung function in the Almetra<sup>&reg;</sup><sub> /</sub>cisplatin arm and deterioration of lung function over time in the control arm.</p><p>There are limited data in patients with malignant pleural mesothelioma treated with <sub>Almetra</sub><sup>&reg;</sup><sub> </sub>alone. Almetra<sup>&reg;</sup><sub> </sub>at a dose of 500 mg/m2 was studied as a single-agent in 64 chemonaive patients with malignant pleural mesothelioma. The overall response rate was 14.1 %.</p><p><em><u>NSCLC, second-line treatment:</u></em><em> </em></p><p>A multicentre, randomised, open label phase 3 study of pemetrexed versus docetaxel in patients with locally advanced or metastatic NSCLC after prior chemotherapy has shown median survival times of 8.3 months for patients treated with pemetrexed (Intent To Treat population n = 283) and 7.9 months for patients treated with docetaxel (ITT n = 288). Prior chemotherapy did not include pemetrexed. An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (n = 399, 9.3 versus 8.0 months, adjusted HR = 0.78; 95% CI = 0 .61-1.00, p = 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (n = 172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI = 1.08-2.26, p = 0.018). There were no clinically relevant differences observed for the safety profile of Almetra<sup>&reg; </sup>&nbsp;within the histology subgroups.</p><p>Limited clinical data from a separate randomized, Phase 3, controlled trial, suggest that efficacy data (overall survival, progression free survival) for pemetrexed are similar between patients previously pretreated with docetaxel (n = 41) and patients who did not receive previous docetaxel treatment (n = 540).</p><p>Efficacy of pemetrexed vs docetaxel in NSCLC - ITT population</p><table border="0" cellspacing="0" cellpadding="0" style="width:666px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pemetrexed</strong></p></td><td style="vertical-align:top"><p><strong>Docetaxel</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Survival Time (months)</strong>&nbsp;</p><p>~ Median (m)</p><p>~ 95 % CI for median</p><p>~ HR</p><p>~ 95 % CI for HR</p><p>~ Non-inferiority p-value (HR)</p></td><td style="vertical-align:top"><p>(n = 283)</p><p>8.3</p><p>(7.0 - 9.4)</p></td><td style="vertical-align:top"><p>(n = 288) 7.9 (6.3 - 9.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.99</p><p>(.82 - 1.20)</p><p>.226</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Progression free survival (months)</strong></p><p>~ Median</p><p>~ HR (95 % CI)</p></td><td style="vertical-align:top"><p>(n = 283)</p><p>2.9</p></td><td style="vertical-align:top"><p>(n = 288) 2.9</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.97 (.82 &ndash; 1.16)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Time to treatment failure (TTTF &ndash; months)</strong></p><p>~ Median</p><p>~ HR (95 % CI)</p></td><td style="vertical-align:top"><p>(n = 283)</p><p>2.3</p></td><td style="vertical-align:top"><p>(n = 288) 2.1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.84 (.71 - .997)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response </strong>(n: qualified for response)</p><p>~ Response rate (%) (95 % CI)</p><p>~ Stable disease (%)</p></td><td style="vertical-align:top"><p>(n = 264)</p><p>9.1 (5.9 - 13.2)</p><p>45.8</p></td><td style="vertical-align:top"><p>(n = 274)</p><p>8.8 (5.7 - 12.8)</p><p>46.4</p></td></tr></tbody></table><p>Abbreviations: CI = confidence interval; HR = hazard ratio; ITT = intent to treat; n = total population size.</p><p><em><u>NSCLC, first-line treatment:</u></em><em> </em></p><p>A multicentre, randomised, open-label, Phase 3 study of <sub>Almetra</sub><sup>&reg; </sup>&nbsp;plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic (Stage IIIb or IV)<sub> </sub>non-small cell lung cancer (NSCLC) showed that <sub>Almetra</sub><sup>&reg;&nbsp; </sup>plus cisplatin (Intent-To-Treat</p><p>[ITT] population n = 862) met its primary endpoint and showed similar clinical efficacy as<sub> </sub>gemcitabine plus cisplatin (ITT n = 863) in overall survival (adjusted hazard ratio 0.94; 95% CI =<sub> </sub>0.84-1.05). All patients included in this study had an ECOG performance status 0 or 1.</p><p>The primary efficacy analysis was based on the ITT population. Sensitivity analyses of main efficacy endpoints were also assessed on the Protocol Qualified (PQ) population. The efficacy analyses using PQ population are consistent with the analyses for the ITT population and support the non-inferiority of AC versus GC.</p><p>Progression free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI = 0.94-1.15), and overall response rate was 30.6% (95% CI = 27.3-33.9) for pemetrexed plus cisplatin versus 28.2% (95% CI = 25.0-31.4) for gemcitabine plus cisplatin. PFS data were partially confirmed by an independent review (400/1725 patients were randomly selected for review).</p><p>The analysis of the impact of NSCLC histology on overall survival demonstrated clinically relevant differences in survival according to histology, see table below.</p><p><strong>Efficacy of Almetra<sup>&reg;</sup></strong><strong><sub> </sub></strong><strong>&nbsp;+ cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer &ndash; ITT population and histology subgroups.</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:690px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>ITT population and histology subgroups</strong>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Median overall survival in months</strong></p><p><strong>(95% CI)</strong>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Adjusted hazard ratio </strong></p><p><strong>(HR) (95% CI)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Superiority p-value</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Almetra<sup>&reg;</sup>&nbsp; + cisplatin</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine + cisplatin</strong></p></td></tr><tr><td style="vertical-align:top"><p>ITT population</p><p>(N = 1725)</p></td><td style="vertical-align:top"><p>10.3</p><p>(9.8 &ndash; 11.2)</p></td><td style="vertical-align:top"><p>N=862</p></td><td style="vertical-align:top"><p>10.3</p><p>(9.6 &ndash; 10.9)</p></td><td style="vertical-align:top"><p>N=863</p></td><td style="vertical-align:top"><p>0.94<sup>a</sup></p><p>(0.84 &ndash; 1.05)</p></td><td style="vertical-align:top"><p>0.259</p></td></tr><tr><td style="vertical-align:top"><p>Adenocarcinoma</p><p>(N=847)</p></td><td style="vertical-align:top"><p>12.6&nbsp;</p><p>(10.7 &ndash; 13.6)</p></td><td style="vertical-align:top"><p>N=436</p></td><td style="vertical-align:top"><p>10.9&nbsp;</p><p>(10.2 &ndash; 11.9)</p></td><td style="vertical-align:top"><p>N=411</p></td><td style="vertical-align:top"><p>0.84</p><p>(0.71&ndash;0.99)</p></td><td style="vertical-align:top"><p>0.033</p></td></tr><tr><td style="vertical-align:top"><p>Large cell</p><p>(N=153)</p></td><td style="vertical-align:top"><p>10.4</p><p>(8.6 &ndash; 14.1)</p></td><td style="vertical-align:top"><p>N=76</p></td><td style="vertical-align:top"><p>6.7</p><p>(5.5 &ndash; 9.0)</p></td><td style="vertical-align:top"><p>N=77</p></td><td style="vertical-align:top"><p>0.67</p><p>(0.48&ndash;0.96)</p></td><td style="vertical-align:top"><p>0.027</p></td></tr><tr><td style="vertical-align:top"><p>Other</p><p>(N=252)</p></td><td style="vertical-align:top"><p>8.6</p><p>(6.8 &ndash; 10.2)</p></td><td style="vertical-align:top"><p>N=106</p></td><td style="vertical-align:top"><p>9.2</p><p>(8.1 &ndash; 10.6)</p></td><td style="vertical-align:top"><p>N=146</p></td><td style="vertical-align:top"><p>1.08</p><p>(0.81&ndash;1.45)</p></td><td style="vertical-align:top"><p>0.586</p></td></tr><tr><td style="vertical-align:top"><p>Squamous cell</p><p>(N=473)</p></td><td style="vertical-align:top"><p>9.4</p><p>(8.4 &ndash; 10.2)</p></td><td style="vertical-align:top"><p>N=244</p></td><td style="vertical-align:top"><p>10.8</p><p>(9.5 &ndash; 12.1)</p></td><td style="vertical-align:top"><p>N=229</p></td><td style="vertical-align:top"><p>1.23</p><p>(1.00&ndash;1.51)</p></td><td style="vertical-align:top"><p>0.050</p></td></tr></tbody></table><p>Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size.</p><p><sup>a </sup>Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p &lt;0.001).</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_11643" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:390.75pt;height:188.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="521" height="251" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>There were no clinically relevant differences observed for the safety profile of <sub>Almetra</sub><sup>&reg;</sup><sub> </sub>plus cisplatin within the histology subgroups.</p><p>Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p&lt;0.001), red blood cell transfusions (16.1% versus 27.3%, p&lt;0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002). Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p&lt;0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p=0.004), and iron preparations (4.3% versus 7.0%, p=0.021).</p><p><em><u>NSCLC, maintenance treatment:</u></em><em> </em></p><p><em><u>JMEN</u></em><em> </em></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_76466" o:spid="_x0000_s1026"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:0;margin-top:100.75pt;width:476.15pt;height:25.2pt;z-index:251673600;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text' o:allowoverlap="f">
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="635" height="34" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" />A multicentre, randomised, double-blind, placebo-controlled Phase 3 study (JMEN), compared the efficacy and safety of maintenance treatment with pemetrexed plus best supportive care (BSC) (n = 441)<sub> </sub>with that of placebo plus BSC (n = 222) in patients with locally advanced (Stage IIIB) or<sub> </sub>metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) who did not progress after 4 cycles of<sub> </sub>first line doublet therapy containing Cisplatin or Carboplatin in combination with Gemcitabine,<sub> </sub>Paclitaxel, or Docetaxel. First line doublet therapy containing Pemetrexed was not included. All<sub> </sub>patients included in this study had an ECOG performance status 0 or 1. Patients received maintenance<sub> </sub>treatment until disease progression. Efficacy and safety were measured from the time of</p><p>&nbsp;</p><p>(48.3%) completed &ge; 6 cycles and a total of 103 patients (23.4%) completed &ge; 10 cycles of treatment with Almetra<sup>&reg;</sup> .</p><p>The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (n = 581, independently reviewed population; median of 4.0 months and 2.0 months, respectively) (hazard ratio = 0.60, 95% CI = 0.49-0.73, p &lt; 0.00001). The independent review of patient scans confirmed the findings of the investigator assessment of PFS. The median OS for the overall population (n = 663) was 13.4 months for the pemetrexed arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI = 0.65-0.95, p = 0.01192).</p><p>Consistent with other pemetrexed studies, a difference in efficacy according to NSCLC histology was observed in JMEN. For patients with NSCLC other than predominantly squamous cell histology (n = 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95% CI = 0.37-0.60, p = 0.00001). The median OS for patients with NSCLC other than predominantly squamous cell histology (n = 481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI = 0.56-0.88, p = 0.002). Including the induction phase the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the pemetrexed arm and 13.6 months for the placebo arm, hazard ratio = 0.71 (95% CI = 0.56-0.88, p = 0.002).</p><p>The PFS and OS results in patients with squamous cell histology suggested no advantage for pemetrexed over placebo.</p><p>There were no clinically relevant differences observed for the safety profile of pemetrexed within the histology subgroups.</p><p>JMEN: Kaplan Meier plots of progression-free survival (PFS) and overall survival pemetrexedversus placebo in patients with NSCLC other than predominantly squamous cell histology&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_11843" o:spid="_x0000_i1026"
 type="#_x0000_t75" style='width:376.5pt;height:181.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
</v:shape><![endif]--><img width="502" height="242" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /></p><p>PARAMOUNT</p><p>A multicentre, randomised, double-blind, placebo-controlled Phase 3 study (PARAMOUNT), compared the efficacy and safety of continuation maintenance treatment with pemetrexed plus BSC (n = 359) with that of placebo plus BSC (n = 180) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC other than predominantly squamous cell histology who did not progress after 4 cycles of first line doublet therapy of pemetrexed in combination with cisplatin. Of the 939 patients treated with pemetrexed plus cisplatin induction, 539 patients were randomised to maintenance treatment with pemetrexed or placebo. Of the randomised patients, 44.9% had a complete/partial response and 51.9% had a response of stable disease to pemetrexed plus cisplatin induction. Patients randomised to maintenance treatment were required to have an ECOG performance status 0 or 1. The median time from the start of pemetrexed plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm. Randomised patients received maintenance treatment until disease progression. Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy. Patients received a median of 4 cycles of maintenance treatment with pemetrexed and 4 cycles of placebo. A total of 169 patients (47.1%) completed &ge; 6 cycles maintenance treatment with pemetrexed, representing at least 10 total cycles of Almetra<sup>&reg;</sup> .</p><p>The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (n = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95% CI = 0.51-0.81, p = 0.0002). The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomised patients, as measured from the start of pemetrexed plus cisplatin first line induction treatment, the median investigator-assessed PFS was 6.9 months for the pemetrexed arm and 5.6</p><p>months for the placebo arm (hazard ratio = 0.59 95% CI = 0.47-0.74).</p><p>Following <sub>Almetra</sub><sup>&reg;</sup><sub> </sub>plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78,</p><p>95%CI=0.64-0.96, p=0.0195). At the time of this final survival analysis, 28.7% of patients were alive or lost to follow up on the pemetrexed arm versus 21.7% on the placebo arm. The relative treatment effect of pemetrexed was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses. The 1 year and 2 year survival rates for patients on pemetrexed were 58% and 32% respectively, compared to 45% and 21% for patients on placebo. From the start of pemetrexed plus cisplatin first line induction treatment, the median OS of patients was 16.9 months for the pemetrexed arm and 14.0 months for the placebo arm (hazard ratio= 0.78, 95% CI= 0.640.96). The percentage of patients that received post study treatment was 64.3% for pemetrexed and</p><p>71.7% for placebo.</p><p>PARAMOUNT: Kaplan Meier plot of progression-free survival (PFS) and Overall Survival (OS) for continuation pemetrexed maintenance versus placebo in patients with NSCLC other than predominantly squamous cell histology (measured from randomisation)&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_11948" o:spid="_x0000_i1025"
 type="#_x0000_t75" style='width:387pt;height:178.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
  o:title=""/>
</v:shape><![endif]--><img width="516" height="238" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /></p><p>The <sub>Almetra</sub><sup>&reg;</sup><sub> </sub>&nbsp;maintenance safety profiles from the two studies JMEN and PARAMOUNT were similar.</p><p>5.2 Pharmacokinetic properties</p><p>The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 838 mg/m2 infused over a 10-minute period. Pemetrexed has a steady-state volume of distribution of 9 l/m2. In vitro studies indicate that pemetrexed is approximately 81 % bound to plasma proteins. Binding was not notably affected by varying degrees of renal impairment. Pemetrexed undergoes limited hepatic metabolism. Pemetrexed is primarily eliminated in the urine, with 70 % to 90 % of the administered dose being recovered unchanged in urine within the first 24 hours following administration. In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter. Pemetrexed total systemic clearance is 91.8 ml/min and the elimination half-life from plasma is 3.5 hours in patients with normal renal function (creatinine clearance of 90 ml/min). Between patient variability in clearance is moderate at 19.3 %. Pemetrexed total systemic exposure (AUC) and maximum plasma concentration increase proportionally with dose. The pharmacokinetics of pemetrexed are consistent over multiple treatment cycles.</p><p>The pharmacokinetic properties of pemetrexed are not influenced by concurrently administered cisplatin. Oral folic acid and intramuscular Vitamin B12 supplementation do not affect the pharmacokinetics of pemetrexed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 838 mg/m2 infused over a 10-minute period. Pemetrexed has a steady-state volume of distribution of 9 l/m2. In vitro studies indicate that pemetrexed is approximately 81 % bound to plasma proteins. Binding was not notably affected by varying degrees of renal impairment. Pemetrexed undergoes limited hepatic metabolism. Pemetrexed is primarily eliminated in the urine, with 70 % to 90 % of the administered dose being recovered unchanged in urine within the first 24 hours following administration. In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter. Pemetrexed total systemic clearance is 91.8 ml/min and the elimination half-life from plasma is 3.5 hours in patients with normal renal function (creatinine clearance of 90 ml/min). Between patient variability in clearance is moderate at 19.3 %. Pemetrexed total systemic exposure (AUC) and maximum plasma concentration increase proportionally with dose. The pharmacokinetics of pemetrexed are consistent over multiple treatment cycles.</p><p>The pharmacokinetic properties of pemetrexed are not influenced by concurrently administered cisplatin. Oral folic acid and intramuscular Vitamin B12 supplementation do not affect the pharmacokinetics of pemetrexed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of pemetrexed to pregnant mice resulted in decreased foetal viability, decreased foetal weight, incomplete ossification of some skeletal structures and cleft palate.</p><p>Administration of pemetrexed to male mice resulted in reproductive toxicity characterised by reduced fertility rates and testicular atrophy. In a study conducted in beagle dog by intravenous bolus injection for 9 months, testicular findings (degeneration/necrosis of the seminiferous epithelium) have been observed. This suggests that pemetrexed may impair male fertility. Female fertility was not investigated.</p><p>Pemetrexed was not mutagenic in either the in vitro chromosome aberration test in Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be clastogenic in the in vivo micronucleus test in the mouse.</p><p>Studies to assess the carcinogenic potential of pemetrexed have not been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&Oslash;&nbsp; Mannitol</p><p>&Oslash;&nbsp; Hydrochloric acid (<em>for pH adjustment</em>)</p><p>&Oslash;&nbsp; Sodium hydroxide (<em>for pH adjustment</em>)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer&#39;s injection and Ringer&#39;s injection. In the absence of other compatibility studies this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial: 3 years 
Reconstituted and infusion solutions: 
When prepared as directed, reconstituted and further diluted infusion solutions of Almetra® contain no antimicrobial preservatives. Chemical and physical in-use stability of reconstituted and further diluted infusion solutions of pemetrexed were demonstrated for 24 hours at refrigerated temperature (2-8°C).  
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2°C to 8°C. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>below 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Almetra<sup>&reg;</sup> 500 mg powder for concentrate for solution for infusion:&nbsp; </strong>Type I glass vial with rubber stopper.&nbsp;</p><p>Pack of 1 vial.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use aseptic technique during the reconstitution and further dilution of pemetrexed for intravenousinfusion administration.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the dose and the number of <strong>Almetra<sup>&reg;</sup></strong> vials needed. Each vial contains an excess of pemetrexed to facilitate delivery of label amount.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reconstitute 500-mg vials with 20 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection,without preservative, resulting in a solution containing 25 mg/ml pemetrexed. Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality. The pH of the reconstituted solution is between 6.6 and 7.8. Further dilution is required.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 mlwith sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pemetrexed infusion solutions prepared as directed above are compatible with polyvinyl chlorideand polyolefin lined administration sets and infusion bags.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral medicinal products must be inspected visually for particulate matter and discolourationprior to administration. If particulate matter is observed, do not administer.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pemetrexed solutions are for single use only. Any unused medicinal product or waste material mustbe disposed of in accordance with local requirements for cytotoxic medicinal products.</p><p><strong>Preparation and administration precautions:</strong> As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of pemetrexed infusion solutions, especially by pregnant staff. The use of gloves is recommended. If a pemetrexed solution contacts the skin, wash the skin immediately and thoroughly with soap and water. If pemetrexed solutions contact the mucous membranes, flush thoroughly with water. Pemetrexed is not a vesicant. There is not a specific antidote for extravasation of pemetrexed. There have been few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator. Extravasation should be managed by local standard practice as with other non-vesicants.</p><p>The reconstituted solution is a clear, colorless to yellow or yellow-green colored solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi 
King Abdulaziz road - Alrabea District 
Grand Center 1st floor – Front of Kingdom Hospital 
P.O Box 47315 Riyadh, 13456 Saudi Arabia
Phone: + 966112790122
Fax: +966112471323
E-mail: Albaraa.bahhari@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 January 2019 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>